+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030- Product Image
Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030- Product Image
New

Pharmacovigilance Market Size, Share & Trends Analysis Report By Product Life Cycle, By Service Provider (In-house, Contract Outsourcing), By Type, By Therapeutic Area, By Process Flow, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 120 Pages
  • June 2025
  • Region: Global
  • Grand View Research
  • ID: 4764570
Description Jump to:

Pharmacovigilance Market Growth & Trends

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030. It is anticipated to witness growth at a CAGR of 6.5% from 2025 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled “Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study” revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundação Instituto de Pesquisas Farmacêuticas) and Pharmacy College (Universidade de São Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed’s earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights

  • Phase IV dominated the market with a revenue share of over 75.90% in 2024. This was driven by increased ADR incidents and post-marketing surveillance
  • contract outsourcing segment held the largest market share in in the service provider segment in 2024, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
  • Spontaneous reporting segment dominated the pharmacovigilance market in 2024 with the largest share. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
  • Oncology held the largest share of over 27.14% in the therapeutic area segment in 2024, fueled by biopharmaceutical companies’ research efforts in chronic cancer treatments
  • Case data management is anticipated to grow at the fastest CAGR in the process flow segment during the forecast period
  • The biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
  • North America held the largest revenue share of over 32.11% in 2024 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
  • Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product Life Cycle
1.2.2. Service Provider
1.2.3. Type
1.2.4. Process Flow
1.2.5. Therapeutic area
1.2.6. End use
1.2.7. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.5.4.1. Details of Primary Research
1.5.4.2. Data for primary interviews in North America
1.5.4.3. Data for Primary Interviews in Europe
1.5.4.4. Data for Primary Interviews in APAC
1.5.4.5. Data for Primary Interviews in Latin America
1.5.4.6. Data for Primary Interviews in MEA
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Report Objectives
1.10.1. Objective-1
1.10.2. Objective-2
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.2.1. Segment Snapshot (Product Life Cycle & Type)
2.2.2. Segment Snapshot (Process Flow & Therapeutic Area)
2.2.3. Segment Snapshot (End Use)
2.2.4. Competitive Landscape Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing drug consumption and drug development rates
3.2.1.2. Increasing incidence of ADR and drug toxicity
3.2.1.3. Increasing trend of outsourcing pharmacovigilance services
3.2.1.4. Increasing externalization of clinical trial studies by large
3.2.1.5. Increasing Regulatory Burden on Manufacturers
3.2.1.6. Introduction of technologically advanced software services
3.2.1.6.1. Key focus areas for the pharmaceutical/healthcare companies
3.2.1.6.2. Adoption of technological advancements in Life sciences industry
3.2.1.6.3. Published Survey insights - related to adoption of pharmacovigilance automation
3.2.1.7. Rising investment on R&D by healthcare companies
3.2.1.8. Partnerships and collaborations between market players
3.2.2. Market Restraint Analysis
3.2.2.1. Shortage of skilled labor
3.2.2.2. Expensive technology for small and mid-sized player
3.2.2.3. Lack of recognition
3.2.2.4. Scarcity of integration standards
3.2.3. Industry Opportunity Analysis
3.2.4. Industry Challenge Analysis
3.3. Porter’s Five Forces Analysis
3.3.1. Supplier power
3.3.2. Buyer power
3.3.3. Substitution threat
3.3.4. Threat of new entrant
3.3.5. Competitive rivalry
3.4. PESTLE Analysis
3.5. Value Chain Analysis
3.5.1. Preclinical
3.5.2. Clinical
3.5.3. PMA
3.6. Mapping of Life Cycle Against Service Offering and Their Demand
3.7. Regulatory Framework
3.7.1. List of regulatory bodies by Country
3.8. Pricing Models
3.8.1. Drug safety budget allocation by activities
3.8.2. By development phase
3.8.3. By therapeutic area
3.8.4. Pricing level
3.8.4.1. Project management
3.8.4.2. Case processing
3.8.4.3. ADR Reporting
3.8.4.4. Medical writing
3.8.4.5. Drug safety management
3.9. Technology Timeline Overview
3.9.1. Changing Technology & Adoption
3.9.2. Current Technology Landscape of PV
3.9.3. IQVIA's AI-Driven Transformation in Pharmacovigilance
3.9.4. Tech Mahindra’s AI-Driven Pharmacovigilance Solution in
3.9.5. The evolving PV workload with AI assistance
3.9.6. Social Media
3.9.6.1. Literature screening
3.9.6.2. Automation and AI
3.9.6.3. Big data analytics in PV
3.10. COVID-19 Impact Analysis
3.10.1. Developments & Strategic Outcomes
3.10.1.1. Regulatory requirements/changes due to COVID-19
3.10.1.2. Strategies implemented by companies
3.10.1.2.1. IQVIA
3.10.1.2.2. IBM Corporation
3.10.1.2.3. ArisGlobal
3.10.1.2.4. PAREXEL International Corporation
3.10.1.2.5. Bioclinica
3.10.1.2.6. Pharmaceutical Product Development (PPD)
3.10.1.2.7. ICON, plc
3.10.1.2.8. PRA Health Sciences
3.10.1.2.9. Linical Accelovance
3.10.1.2.10. Laboratory Corporation of America Holdings
3.11. Market Trend
3.11.1. Scaling of resources
3.11.2. Automation in Pharmacovigilance
3.12. Impact of Inflation
3.13. Case Studies
3.13.1. Potential Customers
3.13.2. Notable Use Cases
3.13.3. Case Study 1
3.13.3.1. Part 1
3.13.3.2. Part 2
3.13.4. Case Study 2
3.13.5. Case Study 3
3.13.6. Case Study 4
Chapter 4. Pharmacovigilance Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. Product Market Share Movement Analysis, 2024 & 2030
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.3.1. Preclinical
4.3.1.1. Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.2. Phase I
4.3.2.1. Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.3. Phase II
4.3.3.1. Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.4. Phase III
4.3.4.1. Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
4.3.5. Phase IV
4.3.5.1. Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 5. Pharmacovigilance Market: Service Provider Estimates & Trend Analysis
5.1. Service Provider Dashboard
5.2. Service Provider Market Share Movement Analysis, 2024 & 2030
5.3. Market Size & Forecasts and Trend Analysis, by Service Provider, 2018 to 2030 (USD Million)
5.4. In House
5.4.1. In-house market, 2018 - 2030 (USD Million)
5.5. Contract Outsourcing
5.5.1. Contract Outsourcing market, 2018 - 2030 (USD Million)
Chapter 6. Pharmacovigilance Market: Type Estimates & Trend Analysis
6.1. Type Segment Dashboard
6.2. Type Market Share Movement Analysis, 2024 & 2030
6.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
6.4. Spontaneous Reporting
6.4.1. Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
6.5. Intensified ADR Reporting
6.5.1. Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
6.6. Targeted Spontaneous Reporting
6.6.1. Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
6.7. Cohort Event Monitoring (CEM)
6.7.1. CEM market estimates and forecasts, 2018 - 2030 (USD Million)
6.8. EHR Mining
6.8.1. EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 7. Pharmacovigilance Market: Process Flow Estimates & Trend Analysis
7.1. Process Flow Segment Dashboard
7.2. Process Flow Market Share Movement Analysis, 2024 & 2030
7.3. Market Size & Forecasts and Trend Analysis, by Process Flow, 2018 to 2030 (USD Million)
7.4. Case data management
7.4.1. Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
7.4.1.1. Case logging
7.4.1.1.1. Case logging market, 2018 - 2030 (USD Million)
7.4.1.2. Case data analysis
7.4.1.2.1. Case data analysis market, 2018 - 2030 (USD Million)
7.4.1.3. Medical reviewing and reporting
7.4.1.3.1. Medical reviewing and reporting market, 2018 - 2030 (USD Million)
7.5. Signal detection
7.5.1. Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
7.5.1.1. Adverse Event Logging
7.5.1.1.1. Adverse event logging market, 2018 - 2030 (USD Million)
7.5.1.2. Adverse Event Analysis
7.5.1.2.1. Adverse Event Analysis market, 2018 - 2030 (USD Million)
7.5.1.3. Adverse Event Review & Reporting
7.5.1.3.1. Adverse Event Review & Reporting market, 2018 - 2030 (USD Million)
7.6. Risk Management System
7.6.1. Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
7.6.1.1. Risk Evaluation System
7.6.1.1.1. Risk Evaluation market, 2018 - 2030 (USD Million)
7.6.1.2. Risk Mitigation System
7.6.1.2.1. Risk Mitigation market, 2018 - 2030 (USD Million)
Chapter 8. Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis
8.1. Therapeutic Area Segment Dashboard
8.2. Therapeutic Area Market Share Movement Analysis, 2024 & 2030
8.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
8.4. Oncology
8.4.1. Oncology market, 2018 - 2030 (USD Million)
8.5. Neurology
8.5.1. Neurology market, 2018 - 2030 (USD Million)
8.6. Respiratory Systems
8.6.1. Respiratory Systems market, 2018 - 2030 (USD Million)
8.7. Others
8.7.1. Other market, 2018 - 2030 (USD Million)
8.8. Neurology
Chapter 9. Pharmacovigilance Market: Regional Estimates & Trend Analysis
9.1. Regional Market Dashboard
9.2. Regional Market: Key Takeaways
9.3. North America
9.3.1. North America Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.3.2. U.S.
9.3.2.1. Key country dynamic
9.3.2.2. Regulatory framework
9.3.2.3. Competitive insights
9.3.2.4. U.S. Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.3.3. Canada
9.3.3.1. Key country dynamic
9.3.3.2. Regulatory framework
9.3.3.3. Competitive insights
9.3.3.4. Canada Pharmacovigilance market estimates and forecasts, 2018 - 2030
9.3.4. Mexico
9.3.4.1. Key country dynamic
9.3.4.2. Regulatory framework
9.3.4.3. Competitive insights
9.3.4.4. Mexico Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4. Europe
9.4.1. Europe Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.2. Germany
9.4.2.1. Key country dynamic
9.4.2.2. Regulatory framework
9.4.2.3. Competitive insights
9.4.2.4. Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.3. UK
9.4.3.1. Key country dynamic
9.4.3.2. Regulatory framework
9.4.3.3. Competitive insights
9.4.3.4. UK Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.4. France
9.4.4.1. Key country dynamic
9.4.4.2. Regulatory framework
9.4.4.3. Competitive insights
9.4.4.4. France Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.5. Italy
9.4.5.1. Key country dynamic
9.4.5.2. Regulatory framework
9.4.5.3. Competitive insights
9.4.5.4. Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.6. Spain
9.4.6.1. Key country dynamic
9.4.6.2. Regulatory framework
9.4.6.3. Competitive insights
9.4.6.4. Spain Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.7. Russia
9.4.7.1. Key country dynamic
9.4.7.2. Regulatory framework
9.4.7.3. Competitive insights
9.4.7.4. Russia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.8. Denmark
9.4.8.1. Key country dynamic
9.4.8.2. Regulatory framework
9.4.8.3. Competitive insights
9.4.8.4. Denmark Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.9. Sweden
9.4.9.1. Key country dynamic
9.4.9.2. Regulatory framework
9.4.9.3. Competitive insights
9.4.9.4. Sweden Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.4.10. Norway
9.4.10.1. Key country dynamic
9.4.10.2. Regulatory framework
9.4.10.3. Competitive insights
9.4.10.4. Norway Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.5. Asia Pacific
9.5.1. Asia Pacific Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.2. Japan
9.5.2.1. Key country dynamic
9.5.2.2. Regulatory framework
9.5.2.3. Competitive insights
9.5.2.4. Japan Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.3. China
9.5.3.1. Key country dynamic
9.5.3.2. Regulatory framework
9.5.3.3. Competitive insights
9.5.3.4. China Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.4. India
9.5.4.1. Key country dynamic
9.5.4.2. Regulatory framework
9.5.4.3. Competitive insights
9.5.4.4. India Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.5. South Korea
9.5.5.1. Key country dynamic
9.5.5.2. Regulatory framework
9.5.5.3. Competitive insights
9.5.5.4. South Korea Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.6. Australia
9.5.6.1. Key country dynamic
9.5.6.2. Regulatory framework
9.5.6.3. Competitive insights
9.5.6.4. Australia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.5.7. Thailand
9.5.7.1. Key country dynamic
9.5.7.2. Regulatory framework
9.5.7.3. Competitive insights
9.5.7.4. Thailand Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.6. Latin America
9.6.1. Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.2. Brazil
9.6.2.1. Key country dynamic
9.6.2.2. Regulatory framework
9.6.2.3. Competitive insights
9.6.2.4. Brazil Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.6.2.5. (USD Million)
9.6.3. Argentina
9.6.3.1. Key country dynamic
9.6.3.2. Regulatory framework
9.6.3.3. Competitive insights
9.6.3.4. Argentina Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.7. MEA
9.7.1. MEA Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.7.2. South Africa
9.7.2.1. Key country dynamic
9.7.2.2. Regulatory framework
9.7.2.3. Competitive insights
9.7.2.4. South Africa Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.7.3. Saudi Arabia
9.7.3.1. Key country dynamic
9.7.3.2. Regulatory framework
9.7.3.3. Competitive insights
9.7.3.4. Saudi Arabia Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.7.4. UAE
9.7.4.1. Key country dynamic
9.7.4.2. Regulatory framework
9.7.4.3. Competitive insights
9.7.4.4. UAE Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
9.7.5. Kuwait
9.7.5.1. Key country dynamic
9.7.5.2. Regulatory framework
9.7.5.3. Competitive insights
9.7.5.4. Kuwait Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
Chapter 10. Pharmacovigilance Market: Competitive Analysis
10.1. Market Participant Categorization
10.2. Public Companies
10.2.1. Company Market Position Analysis
10.2.2. Company Market Share Analysis
10.3. Competitive Factors and Strategies
10.3.1. Increasing Strategic Collaborations and Product Launches
10.3.2. Strategic Government initiatives, including collaborations
10.3.3. Competitors increased PV Awareness programs
10.3.4. Competitors increased collaboration and outsourcing of operations
10.3.5. Consolidation Trends
Chapter 11. Competitive Landscape
11.1. Company Profiles
11.1.1. Accenture
11.1.1.1. Overview
11.1.1.2. Financial performance
11.1.1.3. Product benchmarking
11.1.1.4. Strategic initiatives
11.1.2. IQVIA Inc.
11.1.2.1. Overview
11.1.2.2. Financial performance
11.1.2.3. Product benchmarking
11.1.2.4. Strategic initiatives
11.1.3. Cognizant
11.1.3.1. Overview
11.1.3.2. Financial performance
11.1.3.3. Product benchmarking
11.1.3.4. Strategic initiatives
11.1.4. Clinquest Group B.V. (Linical Americas)
11.1.4.1. Overview
11.1.4.2. Financial performance
11.1.4.3. Product benchmarking
11.1.4.4. Strategic initiatives
11.1.5. IBM
11.1.5.1. Overview
11.1.5.2. Financial performance
11.1.5.3. Product benchmarking
11.1.5.4. Strategic initiatives
11.1.6. Laboratory Corporation of America Holdings
11.1.6.1. Overview
11.1.6.2. Financial performance
11.1.6.3. Product benchmarking
11.1.6.4. Strategic initiatives
11.1.7. ArisGlobal
11.1.7.1. Overview
11.1.7.2. Financial performance
11.1.7.3. Product benchmarking
11.1.7.4. Strategic initiatives
11.1.8. Capgemini
11.1.8.1. Overview
11.1.8.2. Financial performance
11.1.8.3. Product benchmarking
11.1.8.4. Strategic initiatives
11.1.9. ITClinical
11.1.9.1. Overview
11.1.9.2. Financial performance
11.1.9.3. Products & Services benchmarking
11.1.9.4. Strategic initiatives
11.1.10. ICON plc.
11.1.10.1. Overview
11.1.10.2. Financial performance
11.1.10.3. Product benchmarking
11.1.10.4. Strategic initiatives
11.1.11. TAKE Solutions Limited
11.1.11.1. Overview
11.1.11.2. Financial performance
11.1.11.3. Product benchmarking
11.1.11.4. Strategic initiatives
11.1.12. Parexel International (MA) Corporation
11.1.12.1. Overview
11.1.12.2. Financial performance
11.1.12.3. Product benchmarking
11.1.12.4. Strategic initiatives
11.1.13. Wipro
11.1.13.1. Overview
11.1.13.2. Financial performance
11.1.13.3. Product benchmarking
11.1.13.4. Strategic initiatives
11.1.14. United BioSource LLC
11.1.14.1. Overview
11.1.14.2. Financial performance
11.1.14.3. Product benchmarking
11.1.14.4. Strategic initiatives
11.1.15. BioClinica Inc. (Clario)
11.1.15.1. Overview
11.1.15.2. Financial performance
11.1.15.3. Product benchmarking
11.1.15.4. Strategic initiatives
11.1.16. ClinChoice (formerly FMD K&L)
11.1.16.1. Overview
11.1.16.2. Financial performance
11.1.16.3. Product benchmarking
11.1.16.4. Strategic initiatives
Chapter 12. Winning Strategies
12.1. Key Winning / Scoring Criteria
12.1.1. By Categories
12.1.1.1. Pharmaceuticals
12.1.1.2. Biotech companies
12.1.1.3. Medical device companies
12.1.2. Key Vendor Selection Factors
12.1.2.1. By Category
12.1.2.2. BY Company size
12.1.2.2.1.1. Key Takeaways
Chapter 13. Switching Cost Analysis
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. North America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
Table 4. North America Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
Table 5. North America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 6. North America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 7. North America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 8. North America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 9. North America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 10. U.S. Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 11. U.S. Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 12. U.S. Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 13. U.S. Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 14. U.S. Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 15. U.S. Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
Table 16. Canada Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 17. Canada Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 18. Canada Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 19. Canada Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 20. Canada Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 21. Canada Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
Table 22. Mexico Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 23. Mexico Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 24. Mexico Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 25. Mexico Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 26. Mexico Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 27. Mexico Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
Table 28. Europe Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 29. Europe Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 30. Europe Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 31. Europe Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 32. Europe Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 33. Europe Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 34. UK Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 35. UK Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 36. UK Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 37. UK Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 38. UK Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 39. UK Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 40. Germany Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 41. Germany Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 42. Germany Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 43. Germany Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 44. Germany Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 45. Germany Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 46. France Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 47. France Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 48. France Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 49. France Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 50. France Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 51. France Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 52. Italy Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 53. Italy Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 54. Italy Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 55. Italy Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 56. Italy Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 57. Italy Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 58. Spain Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 59. Spain Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 60. Spain Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 61. Spain Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 62. Spain Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 63. Spain Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 64. Russia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 65. Russia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 66. Russia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 67. Russia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 68. Russia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 69. Russia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 70. Norway Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 71. Norway Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 72. Norway Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 73. Norway Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 74. Norway Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 75. Norway Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 76. Sweden Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 77. Sweden Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 78. Sweden Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 79. Sweden Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 80. Sweden Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 81. Sweden Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 82. Denmark Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 83. Denmark Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 84. Denmark Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 85. Denmark Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 86. Denmark Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 87. Denmark Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 88. Asia Pacific Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
Table 89. Asia Pacific Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 90. Asia Pacific Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 91. Asia Pacific Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 92. Asia Pacific Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 93. Asia Pacific Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 94. Asia Pacific Pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
Table 95. Japan Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 96. Japan Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 97. Japan Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 98. Japan Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 99. Japan Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 100. China Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 101. China Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 102. China Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 103. China Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 104. China Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 105. China Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 106. India Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 107. India Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 108. India Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 109. India Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 110. India Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 111. India Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 112. Australia Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 113. Australia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 114. Australia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 115. Australia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 116. Australia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 117. Australia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 118. South Korea Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
Table 119. South Korea Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 120. South Korea Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 121. South Korea Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 122. South Korea Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 123. South Korea Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 124. Thailand Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
Table 125. Thailand Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 126. Thailand Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 127. Thailand Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 128. Thailand Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 129. Thailand Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 130. Latin America Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
Table 131. Latin America Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 132. Latin America Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 133. Latin America Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 134. Latin America Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 135. Latin America Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 136. Latin America Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 137. Brazil Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 138. Brazil Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 139. Brazil Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 140. Brazil Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 141. Brazil Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 142. Brazil Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 143. Argentina Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 144. Argentina Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 145. Argentina Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 146. Argentina Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 147. Argentina Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 148. Argentina Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 149. Middle East & Africa Pharmacovigilance market, by country, 2018 - 2030 (USD Million)
Table 150. Middle East & Africa Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 151. Middle East & Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 152. Middle East & Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 153. Middle East & Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 154. Middle East & Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 155. Middle East & Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 156. South Africa Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
Table 157. South Africa Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 158. South Africa Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 159. South Africa Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 160. South Africa Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 161. South Africa Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 162. Saudi Arabia Pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
Table 163. Saudi Arabia Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 164. Saudi Arabia Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 165. Saudi Arabia Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 166. Saudi Arabia Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 167. Saudi Arabia Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 168. UAE Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 169. UAE Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 170. UAE Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 171. UAE Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 172. UAE Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 173. UAE Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
Table 174. Kuwait Pharmacovigilance market, by product life cycle , 2018 - 2030 (USD Million)
Table 175. Kuwait Pharmacovigilance market, by service provider , 2018 - 2030 (USD Million)
Table 176. Kuwait Pharmacovigilance market, by type, 2018 - 2030 (USD Million)
Table 177. Kuwait Pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
Table 178. Kuwait Pharmacovigilance market, therapeutic area, 2018 - 2030 (USD Million)
Table 179. Kuwait Pharmacovigilance market, end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Pharmacovigilance market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market formulation & validation
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modelling for market share assessment
Fig. 9 Commodity flow analysis
Fig. 10 Market snapshot
Fig. 11 Market segmentation (USD Million)
Fig. 12 Competitive landscape
Fig. 13 Parent market outlook (In USD Billion)
Fig. 14 Related/ancillary market outlook (In USD Billion)
Fig. 15 Pharmacovigilance market dynamics
Fig. 16 Pharmacovigilance market: Porter’s five forces analysis
Fig. 17 Pharmacovigilance market: PESTLE analysis
Fig. 18 Pharmacovigilance market: product life cycle segment dashboard
Fig. 19 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
Fig. 20 Preclinical market, 2018 - 2030 (USD Million)
Fig. 21 Phase I market, 2018 - 2030 (USD Million)
Fig. 22 Phase II market, 2018 - 2030 (USD Million)
Fig. 23 Phase III market, 2018 - 2030 (USD Million)
Fig. 24 Phase IV market, 2018 - 2030 (USD Million)
Fig. 25 Pharmacovigilance market: Service provider movement analysis
Fig. 26 Pharmacovigilance Service provider dashboard
Fig. 27 Pharmacovigilance market: product life cycle segment dashboard
Fig. 28 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
Fig. 29 In-house market, 2018 - 2030 (USD Million)
Fig. 30 contract outsourcing market, 2018 - 2030 (USD Million)
Fig. 31 Pharmacovigilance market: Type movement analysis
Fig. 32 Pharmacovigilance type dashboard
Fig. 33 Pharmacovigilance market: product life cycle segment dashboard
Fig. 34 Pharmacovigilance market: product life cycle market share analysis, 2024 & 2030
Fig. 35 Spontaneous reporting market, 2018 - 2030 (USD Million)
Fig. 36 Intensified ADR reporting market, 2018 - 2030 (USD Million)
Fig. 37 Targeted spontaneous reporting market, 2018 - 2030 (USD Million)
Fig. 38 CEM market, 2018 - 2030 (USD Million)
Fig. 39 EHR mining market, 2018 - 2030 (USD Million)
Fig. 40 Pharmacovigilance market: process flow segment dashboard
Fig. 41 Pharmacovigilance market: process flow market share analysis, 2024 & 2030
Fig. 42 Case data management market, 2018 - 2030 (USD Million)
Fig. 43 Case logging market, 2018 - 2030 (USD Million)
Fig. 44 Case data analysis market, 2018 - 2030 (USD Million)
Fig. 45 Medical reviewing and reporting market, 2018 - 2030 (USD Million)
Fig. 46 Signal detection market, 2018 - 2030 (USD Million)
Fig. 47 Adverse event logging market, 2018 - 2030 (USD Million)
Fig. 48 Adverse event analysis market, 2018 - 2030 (USD Million)
Fig. 49 Adverse event review & reporting market, 2018 - 2030 (USD Million)
Fig. 50 Risk management system market, 2018 - 2030 (USD Million)
Fig. 51 Risk Evaluation System market, 2018 - 2030 (USD Million)
Fig. 52 Risk mitigation system market, 2018 - 2030 (USD Million)
Fig. 53 Pharmacovigilance market: therapeutic area segment dashboard
Fig. 54 Pharmacovigilance market: therapeutic area market share analysis, 2024 & 2030
Fig. 55 Oncology market, 2018 - 2030 (USD Million)
Fig. 56 Neurology market, 2018 - 2030 (USD Million)
Fig. 57 Cardiology market, 2018 - 2030 (USD Million)
Fig. 58 Respiratory systems market, 2018 - 2030 (USD Million)
Fig. 59 Others market, 2018 - 2030 (USD Million)
Fig. 60 Pharmacovigilance market: end use segment dashboard
Fig. 61 Pharmacovigilance market: end use market share analysis, 2024 & 2030
Fig. 62 Pharmaceuticals market, 2018 - 2030 (USD Million)
Fig. 63 Biotechnology companies’ market, 2018 - 2030 (USD Million)
Fig. 64 Medical device manufacturers market, 2018 - 2030 (USD Million)
Fig. 65 Others market, 2018 - 2030 (USD Million)
Fig. 66 Pharmacovigilance market revenue, by region
Fig. 67 Regional marketplace: Key takeaways
Fig. 68 North America Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 US Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 71 Key country dynamics
Fig. 72 Canada Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 Mexico Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Europe Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 UK Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 Germany Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 France Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 83 Key country dynamics
Fig. 84 Italy Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 85 Key country dynamics
Fig. 86 Spain Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 Norway Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 Sweden Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Denmark Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 93 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Japan Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 China Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 India Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 100 Key country dynamics
Fig. 101 Australia Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 102 Key country dynamics
Fig. 103 South Korea Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 104 Key country dynamics
Fig. 105 Thailand Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 106 Latin America Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 107 Key country dynamics
Fig. 108 Brazil Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 109 Key country dynamics
Fig. 110 Argentina Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 111 Key country dynamics
Fig. 112 MEA Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 113 Key country dynamics
Fig. 114 South Africa Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 115 Key country dynamics
Fig. 116 Saudi Arabia Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 117 Key country dynamics
Fig. 118 UAE Pharmacovigilance market, 2018 - 2030 (USD Million)
Fig. 119 Key country dynamics
Fig. 120 Kuwait healthcare information system market, 2018 - 2030 (USD Million)
Fig. 121 Key country dynamics
Fig. 122 Company categorization
Fig. 123 Company market position analysis
Fig. 124 Strategic framework

Companies Mentioned

  • Accenture
  • IQVIA Inc.
  • Cognizant
  • Clinquest Group B.V. (Linical Americas)
  • IBM
  • Laboratory Corporation of America Holdings
  • ArisGlobal
  • Capgemini
  • ITClinical
  • ICON plc.
  • TAKE Solutions Limited
  • Parexel International (MA) Corporation
  • Wipro
  • United BioSource LLC
  • BioClinica Inc. (Clario)
  • ClinChoice (formerly FMD K&L)

Table Information

Report AttributeDetails
No. of Pages120
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.95 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.78 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast to 2030 - Product Image

Pharmacovigilance Market by Type, Product Life Cycle, Delivery Mode, Process Flow, Therapeutic Area, End-user - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Pharmacovigilance & Drug Safety Software Market by Component, Deployment Mode, End User, Application, Organization Size - Global Forecast to 2030 - Product Image

Pharmacovigilance & Drug Safety Software Market by Component, Deployment Mode, End User, Application, Organization Size - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032 - Product Image

Pharmacovigilance Market Report by Service Provider, Product Life Cycle, Type, Process Flow, Therapeutic Area, End Use, and Region 2024-2032

  • Report
  • 135 Pages
  • Global
From
Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2025-2033 - Product Image

Pharmacovigilance and Drug Safety Software Market Report by Functionality, Delivery Mode, End User, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From
Post-Marketing Pharmacovigilance and Medical Information - Global Strategic Business Report - Product Image

Post-Marketing Pharmacovigilance and Medical Information - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.